Memorial Sloan Kettering

51003_MSK_FallNews_K4_Pages

Issue link: http://read.uberflip.com/i/1410380

Contents of this Issue

Navigation

Page 1 of 3

MSK developed the very first drug to improve the lives of people with metastatic melanoma. It was approved by the FDA in 2011. But additional investment is essential to continue improving early detection of skin cancers, which is the core of Dr. Halpern's work. The five-year survival rate of people with local stage I melanoma is 99%. For melanoma that has spread to distant organs, it is 27%. Dr. Halpern's pioneering research makes use of whole-body photography to assist physicians in identifying cancerous moles when they are most treatable. He shared with the Shore brothers a program he is developing to apply artificial intelligence (AI) to skin imaging. It would enable anyone with a smartphone to proactively monitor their skin. Howard and Graham were inspired by Dr. Halpern's early adoption of technology and collaborative approach with researchers at medical centers across the globe. They generously decided to fund the program, known as the International Skin Imaging Collaboration (ISIC), through the Shore Family Fund. The brothers' philanthropic partnership with MSK supports the development of an online database of skin images, which will foster the creation of AI algorithms needed to identify melanoma in its earliest forms. "The holy grail," says Graham, "is an AI-enhanced image that allows the physician to determine if a biopsy is necessary." The siblings hope that their giving to the ISIC project will help accelerate the availability of this life-changing technology at cancer centers throughout the United States and other countries. Howard and Graham are committed to remembering their father by supporting Dr. Halpern's initiative. "At its core, MSK is an amazing institution with forward-thinking research and old-fashioned values," says Howard. "Like our father, the doctors and all the personnel will always put the patient first." PAGE 2 Allan C. Halpern, MD, is an MSK internist and dermatologist whose work focuses on detecting and managing melanoma. He has pioneered the use of whole-body photography to improve early detection of the disease. Honoring Their Father's Legacy of Care Continued from Page 1 PAGE 2 Philanthropy supports and accelerates innovations at MSK at a pace that was unthinkable just a decade ago. The Shore Family Fund will help drive transformational change in the early detection and diagnosis of melanoma." —Dr. Allan Halpern

Articles in this issue

view archives of Memorial Sloan Kettering - 51003_MSK_FallNews_K4_Pages